Dr Emilie Rodenburger
Director, Clinical Affairs
Dr Rodenburger holds a state diploma of Doctor of Pharmacy (PharmD) from the Faculty of Pharmaceutical and Biological Sciences of Paris, Paris V University, a master’s degree in cancer biology from Paris XI University and an inter-university diploma in clinical research from Paris VI University, France. Dr Rodenburger joined CLINUVEL in April 2009 having previously held various roles in fundamental research, retail pharmacies, and with the national competent authority in France. She has held clinical leadership roles for the Group in Australia, the USA and Europe.
Dr Rodenburger oversees the implementation of the post-authorisation measures for SCENESSE® (afamelanotide 16mg) for erythropoietic protoporphyria (EPP) patients in Europe, and leads CLINUVEL’s global clinical development program. She is currently undertaking further training to assume the Chief Scientific Officer role at CLINUVEL.